Firms, funds, people, portfolio companies and transactions from sworn filings and cited announcements, kept as a graph with a date and a source on every edge. Reported gross assets are never fund size, regulatory AUM is never dry powder, and a deal value prints only when someone disclosed it.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Transactions / C••••

A•••••••• C•••••• P••••••• Announces Majority Growth Investment in C••••

Majority investmentannouncedannounced Oct 1, 2025Fact
What happened
Target
C••••
Platform
not an add-on on record
Control
Control
Share acquired
unknown
Industry
unknown
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
8 named
Buy side
  • G••••• A••••••Deal partnerconfirmed
    “G••••• A••••••, a Managing Director at A••••••••, added, “With deep expertise in high-growth areas such as interventional cardiology and structural heart, C•••• is a critical partner to customers in the advancement of innovative and essential treatments and technologies.”
  • M•••••• L••••••• A•••••Deal partnerconfirmed
    ““As the complexity of medical devices and advanced therapeutics continues to rise amid an increasingly stringent regulatory environment, the need for specialized preclinical research services has never been greater,” said Matt A•••••, a Managing Partner at A••••••••.”
  • A•••••••• C•••••• P•••••••Sponsorconfirmed
    “A•••••••• C•••••• P••••••• Announces Majority Growth Investment in C•••• | published on A•••••••• C•••••• P•••••••'s own news page arlingtoncap.com”
Advisory side
  • F•••••••• P•••••••Buy-side adviserconfirmed
    “F•••••••• P••••••• served as financial advisor and D•• P•••• LLP served as legal advisor to A•••••••• C•••••• P•••••••.”
  • D•• P••••Legal adviserconfirmed
    “F•••••••• P••••••• served as financial advisor and D•• P•••• LLP served as legal advisor to A•••••••• C•••••• P•••••••.”
Side not stated
  • E••••• E••••••Managementconfirmed
    “Dr. E••••• E••••••, Co-Founder of C••••, added, “Our collaboration with A•••••••• comes at the perfect time as we respond to the evolving needs of the translational community.”
  • P•••• M••••••Managementconfirmed
    ““As we evolve to meet the needs of an increasingly dynamic industry, we are excited to partner with A•••••••• in this next chapter,” said P•••• M••••••, CEO and Co-Founder of C••••.”
  • C••••Targetconfirmed
    “A•••••••• C•••••• P••••••• Announces Majority Growth Investment in C••••”
Evidence
“A•••••••• C•••••• P••••••• Announces Majority Growth Investment in C••••”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026
A•••••••• C•••••• P••••••• Announces Majority Growth Investment in C•••• | Private Equity Intelligence | DFX